NovaBay Pharmaceuticals shares jumped nearly 19% after the eyecare biotech company announced a strategic rebrand to Stablecoin Development Corporation, signaling a complete pivot from pharmaceutical operations into cryptocurrency development.
The company's rebranding represents an aggressive shift in business focus toward the digital assets sector, where stablecoin infrastructure has become increasingly competitive. The sharp equity rally reflects investor appetite for established public entities entering the crypto space, though the move marks a dramatic departure from NovaBay's historical focus on ophthalmic pharmaceuticals and eye care treatments.
The timing of the rebrand coincides with growing institutional interest in stablecoin protocols and infrastructure, particularly as regulatory frameworks continue to evolve globally. Stablecoins have emerged as critical rails for decentralized finance ecosystems and cross-border payment networks, attracting both venture capital and legacy financial institutions seeking exposure to blockchain infrastructure.